DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ORKAMBI
➤ Subscribe for complete access
« Back to Dashboard
All Clinical Trials for Orkambi
| Trial ID |
Title |
Status |
Sponsor |
Phase |
Start Date |
Summary |
| NCT02170025 ↗ |
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients |
Terminated |
Merck Sharp & Dohme Corp. |
Phase 2 |
2014-09-30 |
Assessment of the safety, tolerability and early signs of efficacy of three times a day
orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on
treatment with Orkambi
|
| NCT02170025 ↗ |
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients |
Terminated |
Bayer |
Phase 2 |
2014-09-30 |
Assessment of the safety, tolerability and early signs of efficacy of three times a day
orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on
treatment with Orkambi
|
| NCT02589236 ↗ |
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation |
Completed |
Medidata Solutions |
Phase 2 |
2015-11-01 |
This will be a double-blind, randomized, placebo-controlled, parallel group study. The
purpose of this study is to investigate the efficacy and safety of Cavosonstat (N91115) in
adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated
with lumacaftor/ivacaftor (Orkambi™).
|
| NCT02589236 ↗ |
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation |
Completed |
Nivalis Therapeutics, Inc. |
Phase 2 |
2015-11-01 |
This will be a double-blind, randomized, placebo-controlled, parallel group study. The
purpose of this study is to investigate the efficacy and safety of Cavosonstat (N91115) in
adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated
with lumacaftor/ivacaftor (Orkambi™).
|
| NCT02653027 ↗ |
Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del |
Withdrawn |
Massachusetts General Hospital |
N/A |
2018-01-01 |
The purpose of this research study is to find out if the combined therapy
lumacaftor-ivacaftor effects how people with cystic fibrosis respond to an oral glucose
tolerance test, a test for diabetes.
|
| >Trial ID |
>Title |
>Status |
>Phase |
>Start Date |
>Summary |
Clinical Trial Conditions for Orkambi
Condition Name
| Condition Name for Orkambi |
| Intervention |
Trials |
| Cystic Fibrosis |
17 |
| Diabetes |
2 |
| Homozygous F508del Mutation |
1 |
| Long QT Syndrome |
1 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Condition MeSH
| Condition MeSH for Orkambi |
| Intervention |
Trials |
| Cystic Fibrosis |
17 |
| Fibrosis |
16 |
| Syndrome |
1 |
| Long QT Syndrome |
1 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Locations for Orkambi
Trials by Country
| Trials by Country for Orkambi |
| Location |
Trials |
| United States |
123 |
| Germany |
9 |
| Canada |
7 |
| France |
5 |
| Italy |
3 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Trials by US State
| Trials by US State for Orkambi |
| Location |
Trials |
| North Carolina |
6 |
| Massachusetts |
6 |
| Illinois |
6 |
| Ohio |
6 |
| Alabama |
5 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Progress for Orkambi
Clinical Trial Phase
| Clinical Trial Phase for Orkambi |
| Clinical Trial Phase |
Trials |
| Phase 4 |
1 |
| Phase 3 |
2 |
| Phase 2 |
6 |
| [disabled in preview] |
5 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Status
| Clinical Trial Status for Orkambi |
| Clinical Trial Phase |
Trials |
| Completed |
7 |
| Recruiting |
6 |
| Terminated |
3 |
| [disabled in preview] |
2 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Sponsors for Orkambi
Sponsor Name
| Sponsor Name for Orkambi |
| Sponsor |
Trials |
| Vertex Pharmaceuticals Incorporated |
4 |
| National Heart, Lung, and Blood Institute (NHLBI) |
2 |
| Children's Hospital Medical Center, Cincinnati |
2 |
| [disabled in preview] |
3 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Sponsor Type
| Sponsor Type for Orkambi |
| Sponsor |
Trials |
| Other |
15 |
| Industry |
11 |
| NIH |
2 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
